AGMBAgomab Therapeutics NVvs its industry peers
A metric-by-metric comparison of Agomab Therapeutics NV against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
Full peer comparison
Peers: same SEC industry (Biological Products, (No Diagnostic Substances))| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGMBThis | — | — | — | — | — | — | — | — | — | — | — | — |
| ABPO | — | — | — | — | 50.0%#3 | 218.1%#1 | -4618.6%#5 | — | — | — | — | — |
| ABPWW | $116152#3 | 0.0x#1 | — | 0.6x#1 | 50.0%#3 | 218.1%#1 | -4618.6%#5 | — | — | — | -60.9%#4 | — |
| ACOG | $178M#2 | — | 3.1x#1 | 17.4x#3 | — | -39.8%#6 | -221.7%#3 | -36.0%#2 | — | — | -23.6%#2 | — |
| ADAPY | — | — | — | — | 195.3%#1 | 37.8%#5 | -38.6%#2 | — | — | — | — | — |
| ADPT | $3.5B#1 | — | 16.0x#2 | 12.5x#2 | 54.8%#2 | 62.7%#4 | -20.6%#1 | -27.5%#1 | -21.2%#1 | — | 79.7%#1 | — |
| ALGS | — | — | — | — | -39.5%#5 | 81.6%#3 | -4024.9%#4 | -76.1%#3 | — | — | -24.8%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice